INEGY 10 MG20 MG TABLETS

Valsts: Izraēla

Valoda: angļu

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

EZETIMIBE; SIMVASTATIN

Pieejams no:

MERCK SHARP & DOHME ISRAEL LTD

ATĶ kods:

C10AA01

Zāļu forma:

TABLETS

Kompozīcija:

SIMVASTATIN 20 MG; EZETIMIBE 10 MG

Ievadīšanas:

PER OS

Receptes veids:

Required

Ražojis:

MERCK SHARP & DOHME B.V., THE NETHERLANDS

Ārstniecības grupa:

SIMVASTATIN

Ārstniecības joma:

SIMVASTATIN

Ārstēšanas norādes:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH.Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Autorizācija datums:

2012-04-30